Navigation Links
Nuvo announces first quarter 2008 financial results
Date:5/1/2008

There are more than 21 million Americans suffering from osteoarthritis, a very painful and debilitating condition, and the United States market for this condition is estimated at US$4 billion annually In December 2006, the U.S. Food and Drug Administration issued an approvable letter that indicated Pennsaid(R) is approvable subject to Nuvo satisfying certain conditions.

About Nuvo Research Inc.

Nuvo is a Canadian drug development company primarily focused on the research and development of drug products that are delivered to and through the skin. Nuvo is also involved in research and development activities involving WF10, a chlorite-based, immunomodulating drug through its 60% interest in Dimethaid AG.

Nuvo believes it is uniquely positioned to research and develop new drug product candidates for delivery to and through the skin using its multiplexed molecular penetration enhancers ("MMPE(TM)"s), that interact with the skin and enhance its permeability thereby allowing certain drug molecules to pass into and through the skin to proximate tissues and its high throughput experimentation systems that allow its scientists to rapidly screen combinations of existing molecular penetration enhancers ("MPE(TM)s") with large numbers of potential drug formulations to measure their ability to permeabilize and permeate the skin. Nuvo's lead product Pennsaid(R), a topical non-steroidal anti-inflammatory drug (NSAID) utilizes the Company's technology to treat the symptoms of osteoarthritis of the knee locally. Nuvo intends to leverage its technologies to create a portfolio of topical and transdermal products targeting a variety of indications. Nuvo Research Inc. is a publicly traded company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany and a research and development facility in San Diego, California. For more information, please visit http://w
'/>"/>

SOURCE Nuvo Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Brookdale Announces First Quarter 2008 Release and Earnings Call
2. Brown & Toland Announces 2007 Financial Results
3. NightHawk Radiology Holdings, Inc. Announces Appointment of David Engert to the Board of Directors
4. NUCRYST Announces Management Realignment and R&D Portfolio Change
5. West Pharmaceutical Services, Inc. Announces Annual Meeting Webcast
6. Renowned ENT Specialist, Dr. Murray Grossan, Announces Medical Breakthrough on Snoring at PRI-MED Convention in Anaheim on May 15-17
7. GSK Announces Changes to Corporate Executive Team
8. Summit VetPharm Announces New Distributor Partnership with Webster Veterinary
9. Psychemedics Corporation Announces First Quarter Results
10. InfoLogix Announces First Quarter 2008 Financial Results
11. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... combining salmon fibrin injections into the spinal cord and ... voluntary motor function impaired by spinal cord injury, scientists ... In a study on rodents, Gail Lewandowski and Oswald ... clock in a molecular pathway critical to the formation ... so that neuronal axons at the injury site could ...
(Date:7/23/2014)... 2014 This report defines and segments ... Europe, the Middle East & Africa, and Americas) - ... geography with analysis and forecasts of the global revenue. ... from over $10 billion in 2014 to nearly $14 ... , browse 49 Market Tables and 10 Figures ...
(Date:7/23/2014)... A Forever Recovery, an open-ended drug ... a great start and gives them a solid foundation ... new Internet Addiction section of its website at ... that Internet addiction is not just as legitimate a ... it’s trapping more and more victims each year – ...
(Date:7/23/2014)... -- Children and teens who lose a parent might face ... new study suggests. People who were children or teens ... of death during the study period than those who had ... report. Although the study found an association between a ... it wasn,t designed to prove cause-and-effect. Also, the increased ...
(Date:7/23/2014)... 2014 SafeUseNow? , a ... developed by Principled Strategies , today announced ... California . Utilizing SafeUseNow’s patent-pending risk model, Partnership ... misusing and abusing controlled substance drugs, particularly prescription ... its members. , The agreement with Partnership HealthPlan ...
Breaking Medicine News(10 mins):Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 3Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 4Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 3Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 4
... artists like Ram Kumar, V S Gaitonde and Jehangir ... of contemporary Indian paintings and sculptures held at Durban ... // ,Since having a cultural co-operation between Indian ... between the gallery like Iziko South African National Gallery ...
... painstaking and reaps benefits only when done with full dedication. ... in Georgetown. This has brought to the world the first cancer ... when on June 8, the Food and Drug Administration approved the ... of HPV. ,In the doctor’s own words, "It's a ...
... colleagues at the Indiana University Medical Center, Indianapolis say ... into having unwanted sex //. ,Unwanted sex ... researchers write in the June issue of the Archives ... result in risk for sexually transmitted infections and pregnancies. ...
... inputs on the manner of T-cells enabling immunity and furthering ... will go a long way in measuring the efficiency of ... ,Led by researchers at Beth Israel Deaconess Medical ... National Institute of Allergy and Infectious Diseases (NIAID), part of ...
... leader Sri Sri Ravishankar has said practising yoga, pranayam and ... alcohol abuse. // ,'Youths crave for something different ... dhyan (meditation) to them,' he said while interacting with reporters ... Kundaim, 15 km from here., ,Ravi Shankar appealed to ...
... that secondhand smoking can be deadly. Hence California and Washington laws ... was 58 years old physically fit suffered from heart problems that ... he worked in smoky taverns for 37 years. So the doctors ... to find that the indoor air pollution levels in bars that ...
Cached Medicine News:Health News:Research on AIDS vaccine a wealth of information 2Health News:Research on AIDS vaccine a wealth of information 3
(Date:7/23/2014)... , July 23, 2014 Inovio ... successful results from its randomized, double-blind, placebo-controlled ... with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) ... or 18. Treatment with VGX-3100, Inovio,s HPV16/18-specific ... to CIN1 or no disease, meeting the ...
(Date:7/23/2014)...  The management team at Columbia Laboratories, Inc. ... conference call on July 31, 2014, to discuss ... 30, 2014.  The call details are as follows:Date: ... EDTDial-in numbers: , Toll free: (877) 870-4263 (U.S.), ... archive): , www.columbialabs.com , under ,Investor, or ...
(Date:7/23/2014)... Global healthcare company GSK reports ... headwinds, increased price competition and supply disruptions to its ... points out that the company is very much in ... be confident about long-term prospects as well as the ... CFO Simon Dingemans adds that the company ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
... SPRING, Md., June 20, 2011 The U.S. Food ... help advance the development and approval of an artificial ... United States. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... condition in which the pancreas produces little or no ...
... (NYSE Amex: CUR ) announced that it has ... Phase Ia trial to test the safety of NSI-189 for ... drug in healthy volunteers for safety and tolerability. NSI-189 is ... new neuron growth in the hippocampus, an area of the ...
Cached Medicine Technology:FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 2FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 3Neuralstem Updates NSI-189 Major Depression Trial 2Neuralstem Updates NSI-189 Major Depression Trial 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: